Peptide-decorated liposomes promote arrest and aggregation of activated platelets under flow on vascular injury relevant protein surfaces in vitro.

Platelet-mimetic synthetic hemostats are highly attractive in transfusion medicine. To this end, past research reports have described particles that either amplify platelet aggregation or mimic platelet adhesion. However, a construct design that effectively combines both functionalities has not been reported. Here we describe the design of a liposomal construct simultaneously surface-decorated with three peptides (a vWF-binding peptide (VBP), a collagen-binding peptide (CBP), and an active platelet clustering cyclic-RGD (cRGD) peptide), that can integrate platelet-mimetic dual hemostatic activities of adhesion and aggregation. We first demonstrate that surface-immobilized cRGD-liposomes are capable of aggregating activated platelets onto themselves. Subsequently, we demonstrate that hetero-multivalent liposomes bearing VBP, CBP, and cRGD, when introduced in flow with ≈ 20,000 activated platelets per microliter, are capable of adhering to vWF/collagen surfaces and promoting the recruitment/aggregation of platelets onto themselves. We envision that optimizing this construct can lead to a highly refined synthetic hemostat design for potential application in transfusion medicine.

[1]  J. Levin,et al.  Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits , 1999, Nature Medicine.

[2]  F. Szoka,et al.  Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. , 1980, Biochimica et biophysica acta.

[3]  Anirban Sen Gupta,et al.  Mimicking adhesive functionalities of blood platelets using ligand-decorated liposomes. , 2012, Bioconjugate chemistry.

[4]  R. d'Oiron,et al.  Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[5]  M. Blajchman,et al.  Novel treatment modalities: new platelet preparations and subsititutes , 2001, British journal of haematology.

[6]  T. Fujie,et al.  Haemostatic effects of polymerized albumin particles carrying fibrinogen γ‐chain dodecapeptide as platelet substitutes in severely thrombocytopenic rabbits , 2008, Transfusion medicine.

[7]  K. Ley,et al.  Shear-dependent inhibition of granulocyte adhesion to cultured endothelium by dextran sulfate. , 1989, Blood.

[8]  K. Ishihara,et al.  Effects of phospholipid adsorption on nonthrombogenicity of polymer with phospholipid polar group. , 1993, Journal of biomedical materials research.

[9]  M. Murata,et al.  Targeting of liposomes carrying recombinant fragments of platelet membrane glycoprotein Ibalpha to immobilized von Willebrand factor under flow conditions. , 2000, Biochemical and biophysical research communications.

[10]  K. Anderson,et al.  Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients , 1995, Transfusion.

[11]  R. d'Oiron,et al.  Recombinant activated factor VII (NovoSeven®) treatment of platelet‐related bleeding disorders , 2000 .

[12]  M. Rybak,et al.  A liposome based platelet substitute, the plateletsome, with hemostatic efficacy. , 1993, Biomaterials, artificial cells, and immobilization biotechnology : official journal of the International Society for Artificial Cells and Immobilization Biotechnology.

[13]  M. Murata,et al.  Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia/IIa and Ib alpha under flow conditions: specific synergy of receptor-ligand interactions. , 2002, Blood.

[14]  J. Baldassare,et al.  Reconstruction of platelet proteins into phospholipid vesicles. Functional proteoliposomes. , 1985, The Journal of clinical investigation.

[15]  M. Misgav,et al.  Recombinant activated factor VII (NovoSeven™): addition to replacement therapy in acute, uncontrolled and life‐threatening bleeding , 2004, Vox sanguinis.

[16]  P. Rebulla,et al.  Platelet transfusions , 2007, The Lancet.

[17]  M. Blajchman,et al.  Platelet substitutes and novel platelet products , 2000, Expert opinion on investigational drugs.

[18]  B. Coller,et al.  Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions. , 1992, Journal of Clinical Investigation.

[19]  T. Fujie,et al.  Development of fibrinogen γ‐chain peptide‐coated, adenosine diphosphate‐encapsulated liposomes as a synthetic platelet substitute , 2009, Journal of thrombosis and haemostasis : JTH.

[20]  J. May,et al.  Interactions of platelets with Synthocytes, a novel platelet substitute. , 2002, Platelets.

[21]  M. Penn,et al.  Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. , 2008, Biomaterials.

[22]  D. Mohanty Current concepts in platelet transfusion , 2009, Asian journal of transfusion science.

[23]  Theo H Smit,et al.  Dynamic shear stress in parallel-plate flow chambers. , 2005, Journal of biomechanics.

[24]  Eishun Tsuchida,et al.  Hemostatic effects of polymerized albumin particles bearing rGPIa/IIa in thrombocytopenic mice. , 2003, Biochemical and biophysical research communications.

[25]  Y. Teramura,et al.  Conjugation of von Willebrand factor-binding domain of platelet glycoprotein Ib alpha to size-controlled albumin microspheres. , 2000, Biomacromolecules.

[26]  Paolo Rebulla,et al.  Transfusion Medicine 2 Platelet transfusions , 2007 .

[27]  Peter Rhee,et al.  QuikClot use in trauma for hemorrhage control: case series of 103 documented uses. , 2008, The Journal of trauma.

[28]  M. Felfernig,et al.  Experience of recombinant activated factor VII (NovoSeven®) in the operating theatre and intensive care unit for the management of intracranial bleeding in nonhaemophilic patients , 2008, Clinical Neurology and Neurosurgery.

[29]  U. Hedner Recombinant factor VIIa (NovoSeven) as a hemostatic agent. , 2001, Disease-a-month : DM.

[30]  N. Blumberg,et al.  Optimizing platelet transfusion therapy. , 2004, Blood reviews.

[31]  Hidenori Suzuki,et al.  New strategy of platelet substitutes for enhancing platelet aggregation at high shear rates: cooperative effects of a mixed system of fibrinogen γ-chain dodecapeptide- or glycoprotein Ibα-conjugated latex beads under flow conditions , 2006, Journal of Artificial Organs.

[32]  Rebecca Robinson,et al.  Intravenous Hemostat: Nanotechnology to Halt Bleeding , 2009, Science Translational Medicine.

[33]  K. Robinson Controlling bleeding in the field: hemostatic powders and dressings debut in the prehospital setting. , 2004, Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association.